CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Allergan, Inc. v. InnoPharma, Inc.

1:15-cv-00815

Overview

Case Number 1:15-cv-00815
Filing Date 2015-09-14
Status Terminated
Termination Date 2015-11-03
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Plaintiff

Parties

Defendant

Pfizer Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

InnoPharma, Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Allergan, Inc. Operating Company

Represented By

2 Attorneys Listed

Susan E. Morrison

Fish & Richardson, P.C.

Tel: +1 (302) 652-8434

222 Delaware Avenue, 17th Floor, P.O. Box 1114

Douglas Edward McCann

Fish & Richardson, P.C.

Tel: +1 (302) 652-5070
Fax: +1 (302) 652-0607

222 Delaware Avenue, 17th Floor, P.O. Box 1114

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials 10 proceedings
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (10 found):
PTAB: 10
USPTO PTAB Trial 2017-01-06
IPR2017-00600

Akorn, Inc. v. Allergan, Inc.

U.S. Continuation Sibling (8648048)
Status: Terminated
USPTO PTAB Trial 2017-01-06
IPR2017-00599

Akorn, Inc. v. Allergan, Inc.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2017-01-06
IPR2017-00598

Akorn, Inc. v. Allergan, Inc.

U.S. Continuation Sibling (8642556)
Status: Final Written Decision
USPTO PTAB Trial 2017-01-06
IPR2017-00596

Akorn, Inc. v. Allergan, Inc.

U.S. Continuation Sibling (8629111)
Status: Terminated
USPTO PTAB Trial 2017-01-06
IPR2017-00594

Akorn, Inc. v. Allergan, Inc.

U.S. Continuation Sibling (8685930)
Status: Terminated
USPTO PTAB Trial 2017-01-06
IPR2017-00585

Teva Pharmaceuticals USA, Inc. v. Allergan, Inc.

U.S. Continuation Sibling (8648048)
Status: Terminated
USPTO PTAB Trial 2017-01-06
IPR2017-00579

Teva Pharmaceuticals USA, Inc. v. Allergan, Inc.

U.S. Continuation Sibling (8642556)
Status: Final Written Decision
USPTO PTAB Trial 2017-01-06
IPR2017-00571

Famy Care Limited v. Allergan, Inc.

U.S. Continuation Sibling (8685930)
Status: Terminated-Settled
USPTO PTAB Trial 2017-01-06
IPR2017-00570

Famy Care Limited v. Allergan, Inc.

U.S. Continuation Sibling (8642556)
Status: Terminated-Settled
USPTO PTAB Trial 2017-01-06
IPR2017-00568

Famy Care Limited v. Allergan, Inc.

Asserted Patent
Status: Terminated-Settled
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

5 Patents

There are 5 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8629111
Methods of providing therapeutic effects using cyclosporin components
Filed: 2013-08-14
Issued: 2014-01-14
Active (6.7 yrs remaining)
Expires: 2033-08-14
US8633162
Methods of providing therapeutic effects using cyclosporin components
Filed: 2013-08-14
Issued: 2014-01-21
Active (6.7 yrs remaining)
Expires: 2033-08-14
US8642556
Methods of providing therapeutic effects using cyclosporin components
Filed: 2013-08-14
Issued: 2014-02-04
Active (6.7 yrs remaining)
Expires: 2033-08-14
US8648048
Methods of providing therapeutic effects using cyclosporin components
Filed: 2013-08-14
Issued: 2014-02-11
Active (6.7 yrs remaining)
Expires: 2033-08-14
US8685930
Methods of providing therapeutic effects using cyclosporin components
Filed: 2013-08-07
Issued: 2014-04-01
Active (6.7 yrs remaining)
Expires: 2033-08-07

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

3

Dispositive

3

Granted

0

Denied

0

Pending / Review

1

Motions by Category

Motion to Dismiss 3

Key Dispositive Motions & Rulings

Motion to Dismiss Pending / Under Review
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s): see report for patent numbers. (Attachments: # 1 Motion to Dismiss)(fms) (E...
Entry #7 • 2015-11-03 Document →
Motion to Dismiss Moot / Terminated
SO ORDERED, re 6 MOTION to Dismiss Based upon parties agreement filed by Allergan, Inc., ***Civil Case Terminated. Signed by Judge Sue L. Robinson on 11/3/2015....
Entry #β€” • 2015-11-03
Motion to Dismiss Moot / Terminated
MOTION to Dismiss Based upon parties agreement - filed by Allergan, Inc.. (Attachments: # 1 Text of Proposed Order)(Coletti, Susan) (Entered: 10/30/2015)
Entry #6 • 2015-10-30 Document →

Docket Entries

(13 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed with Jury Demand against InnoPharma, Inc., Pfizer, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1787044.) - filed by Allergan, Inc. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Civil Cover Sheet)(sec) (Entered: 09/15/2015)

Entry #1 • 2015-09-14
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (sec) (Entered: 09/15/2015)

Entry #2 • 2015-09-14
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 08/03/2015. Date of Expiration of Patent: 08/27/2024.Thirty Month Stay Deadline: 2/3/2018. (sec) (Entered: 09/15/2015)

Entry #3 • 2015-09-14
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,629,111; 8,633,162; 8,642,556; 8,648,048; 8,685,930;. (sec) (Entered: 09/15/2015)

Entry #4 • 2015-09-14
1

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Allergan, Inc.. (Coletti, Susan) (Entered: 09/15/2015)

Entry #5 • 2015-09-15
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc